The overall PFS of 7.4 months compares favorably with those of two key clinical trials that combined hormonal agents with CDK4/6 inhibitors; the latter are key agents in HR+ breast cancer as both first‐line systemic treatment and second‐line or subsequent treatment for hormonal‐therapy‐refractory disease. This evidence concerns the gene CDK4 and breast carcinoma.